The Clinical Therapeutics and Biomedical Prevention Program Section is lead by AIDS Institute Associate Director Ronald Mitsuyasu, MD, and is subdivided into 3 program areas: Microbicides and Other Biomedical Prevention; HIV Immunopathogenesis and Vaccine Concept Development; and HIV Therapeutics.
The Microbicides and Other Biomedical Prevention section is lead by Dr. Pamina Gorbach and Dr. Raphael Landovitz. The section focuses on the study of, optimization of, and implementation science around new prevention technologies being considered for inclusion in combination HIV prevention interventions such as vaginal and rectal microbicides, Antitretroviral Therapy as prevention (Treatment as Prevention [TasP]), Pre-exposure prophylaxis (PrEP), and post-exposure prophylaxis (PEP).
The Immunopathogenesis and Vaccine Concept Development program area, under the leadership of Dr. Otto Yang and Dr. Benhur Lee facilitates inter-disciplinary interest in vaccine development and encourages collaboration on grant applications in all areas related to immunopathogenesis. The HIV Therapeutics area works to strengthen research in all areas of HIV therapy including research on complications and side effects of therapy. This program section is lead by Dr. Karen Nielsen of Pediatrics and IMPAACT and Dr. Judith Currier of the CARE Center and the ACTG.
In addition to these focused sections, the Clinical Therapeutics and Biomedical Prevention Program includes the Clinical Research Facilitation CFAR Core L and the Mucosal Immunology CFAR Core I and also the HIV/AIDS Research Study Volunteer Project.
